Latest revenue
$162.1M
as of 2026-03-31
Latest net income
$-7.0M
as of 2026-03-31
Net margin
-4.3%
as of 2026-03-31
Community sentiment
Where do you think TARS is heading?
Keep private notes on TARS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
TARS vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $1.64B
- Enterprise value
- $1.61B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 4.71×
- Dividend yield
- 0.0%
- 52-wk high
- $85.25
- 52-wk low
- $38.51
- Beta
- —
- Shares out
- 26.7M
What this company does
Item 1. Business Overview We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (“FDA”) approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites. Demodex blepharitis (“blephar” is a reference to eyelid and “itis” is a reference to inflammation) is a disease characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff…
AI summary unavailable — showing raw filing excerpt
Generated from TARS's filing dated 2026-02-23
Key risks
Item 1A. Risk Factors Investing in our common stock is speculative and involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks described below, together with the other information contained in this Annual Report on Form 10-K, including our financial statements and the related notes appearing at the end of this Annual Report on Form 10-K. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. The risks…
AI summary unavailable — showing raw filing excerpt
Generated from TARS's filing dated 2026-02-23
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.